Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoas...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
AB-SWITCH
Evaluation of commercial potential of a low cost kit based o...
150K€
Cerrado
Nano4
Colorimetric Precision Nanodiagnostics made Fast and Afforda...
2M€
Cerrado
Nano4
Providing the New Generation of Nano Based Molecular Technol...
71K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoassays face an important barrier related to reimbursement policy issues when the IVD tests are introduced into national health systems. This barrier discourages many companies from pursuing the development of novel diagnostic tests because the investment necessary to introduce novel IVD tests in the market is hardly matched by the return of the investment. NIMM aims at providing a platform for the development of accurate, sensitive and inexpensive immunoassays for antibody-related conditions using a novel fluorescent nanosensor-based technology. The outcome of the project will pave the way to a commercial product to be sold in the Immunochemistry/Immunoassay segment of the IVD market, currently valued at 15 USD billion. Potential stakeholders in the outcome of NIMM include Public Health authorities and pharmaceutical companies.